drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (gene-modified autologous T cells)
drug_description
Patient-derived T cells genetically engineered to express a chimeric antigen receptor targeting CD1a; upon infusion, CAR signaling (CD3ΞΆ with costimulation) activates cytotoxicity and proliferation to eliminate CD1a-positive T-ALL/LBL cells.
nci_thesaurus_concept_id
C200257
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the T-cell surface glycoprotein CD1a, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD1a CAR T cells bind to and induce selective toxicity in CD1a-expressing tumor cells. CD1a, an antigen-presenting glycoprotein, is exclusively expressed in cortical T-cell acute lymphoblastic leukemia (T-ALL) and otherwise only normally expressed in developing cortical thymocytes and Langerhans cells.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting CD1a. Engagement of CD1a on T-ALL/LBL cells triggers CAR signaling (CD3zeta with costimulatory domains), activating proliferation and cytotoxic effector functions (perforin/granzyme release and cytokine secretion) to selectively kill CD1a-positive tumor cells.
drug_name
Autologous anti-CD1a CAR-T cells
nct_id_drug_ref
NCT05745181